RedHill Biopharma (RDHL) Liabilities and Shareholders Equity (2011 - 2025)

RedHill Biopharma (RDHL) has 15 years of Liabilities and Shareholders Equity data on file, last reported at $25.3 million in Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity rose 40.47% year-over-year to $25.3 million in Q4 2025; TTM through Dec 2025 was $83.8 million, a 14.63% decrease from a year earlier, with the FY2025 full-year figure at $25.3 million, up 40.47% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $25.3 million, up from $18.4 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for RDHL reached as high as $220.1 million in Q1 2021 and fell as low as $18.0 million in Q4 2024.
• Historically, Liabilities and Shareholders Equity has averaged $109.5 million across 5 years, with a median of $157.2 million in 2022.
• Across the five-year window, Liabilities and Shareholders Equity surged 53.42% in 2021 and sank 85.49% in 2023, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $181.2 million in 2021, then decreased by 12.32% to $158.9 million in 2022, then sank by 85.49% to $23.0 million in 2023, then slipped by 21.71% to $18.0 million in 2024, then surged by 40.47% to $25.3 million in 2025.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $25.3 million in Q4 2025, $18.4 million in Q2 2025, and $18.0 million in Q4 2024.